Intravenous iron alone for the treatment of anemia in patients with chronic heart failure
Intravenous iron alone for the treatment of anemia in patients with chronic heart failure
复制标题
DOI：
10.1016/j.jacc.2006.07.015
复制
发表时间：
2006-09-19
影响因子：
24
通讯作者：
Chapman, Callum M.
中科院分区：
文献类型：
--
作者：
Bolger, Aidan P.;Bartlett, Frederick R.;Chapman, Callum M.
本研究旨在评估慢性心力衰竭（CHF）和贫血患者对静脉铁剂的血液学、临床和生化反应。促红细胞生成素（EPO）和铁的组合增加血红蛋白（Hb），改善贫血CHF患者的症状和运动能力。目前尚不清楚静脉铁剂是否是CHF相关贫血的有效治疗方法。
OBJECTIVES This study was undertaken to assess the hematologic, clinical, and biochemical response to intravenous iron in patients with chronic heart failure (CHF) and anemia.BACKGROUND Anemia is common in patients with CHF and is associated with higher morbidity and mortality. The combination of erythropoietin (EPO) and iron increases hemoglobin (Hb) and improves symptoms and exercise capacity In anemic CHF patients. It is not known whether intravenous iron alone is an effective treatment for anemia associated with CHF.METHODS Sixteen anemic patients (Hb